Sterneck Capital Management, LLC Cingulate Inc. Transaction History

Sterneck Capital Management, LLC

  • $172 Million
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 18, 2023
BUY
$0.69 - $328.8 $9,759 - $4.65 Million
14,144 New
14,144 $0

About Cingulate Inc.

CING Quotes by TradingView
  • Ticker CING
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,309,400
  • Market Cap $58.6M
  • Description
  • Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-de...
More about CING
Track This Portfolio

Track Sterneck Capital Management, LLC Portfolio

Follow Sterneck Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sterneck Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sterneck Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email